Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 3571-3580 Newer>

The Motley Fool March 28, 2007 Brian Lawler	AtheroGenics Splices the Data Shares of AtheroGenics will continue to be volatile in the next couple of months as investors await the probable discontinuation of the company's partnership with AstraZeneca.
The Motley Fool March 27, 2007 Ralph Casale	Beckman-Coulter Gets Diagnostic An investor's look at instrument maker Beckman-Coulter's acquisition of medical diagnostic company Biosite.
The Motley Fool March 26, 2007 Rich Duprey	Acquisitions Mark Pharmaceutical Industry Japan's Eisai's newest acquisition continues the trend of pharmaceuticals buying up biotechs. Investors, take note.
The Motley Fool March 23, 2007 Brian Lawler	Mylan TKOs Pfizer Mylan launches a generic version of Pfizer's second-best selling drug. Investors, take note.
The Motley Fool March 21, 2007 Brian Lawler	InterMune Slims Down InterMune announces changes after its lead compound fails in a study. Investors, take note.
The Motley Fool March 21, 2007 Brian Lawler	New Indication for Pain Pain Therapeutics brings a new drug into the clinic. When drug companies attempt to bring new drugs that are outside of their core competencies to market, investors always need to be wary.
The Motley Fool March 21, 2007 Brian Lawler	Acadia Ascending Shares of Acadia Pharmaceuticals soared by more than 100% following successful results from a phase 2 trial for schizophrenia drug candidate ACP-103.
The Motley Fool March 20, 2007 Brian Lawler	A Slowdown at Endo The FDA delays a decision on expanding the label for one of Endo's drugs. Investors, take note.
The Motley Fool March 20, 2007 Brian Lawler	Heart Attack at AtheroGenics Shares of AtheroGenics drop after negative phase 3 trial results.
The Motley Fool March 20, 2007 Brian Lawler	Smart Move by Abbott? Abbott takes a drastic measure to make a point about its patents. Thailand's actions offer a good warning of what can happen when governments try to intervene too much in existing markets.
<Older 3571-3580 Newer> Return to current articles.